drugset
drugset / Trial / NCT07371455

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

NCT07371455 ↗

Phase 1 Recruiting 76 enrolled Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD, and active metabolites of LWP779 after oral administration in healthy participants.

Timeline

Start
2026-03-13
Primary completion
2026-07-10
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject LWP779 Unknown 150 mg Oral
Subject LWP779 Unknown 300 mg Oral
Subject LWP779 Unknown 600 mg Oral
Subject LWP779 Unknown 900 mg Oral
Subject LWP779 Unknown 1200 mg Oral

Indications

ischemic stroke